PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study Evaluating The Safety Of PF-05280014 And Trastuzumab In Healthy Male Volunteers (REFLECTIONS B327-06)
- Conditions
- Healthy
- Interventions
- Biological: PF-05280014Biological: Herceptin®
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2014-04-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 162
- Registration Number
- NCT02015156
- Locations
- 🇺🇸
Pfizer Investigational Site, Overland Park, Kansas, United States
A Bioequivalence Study Comparing A Fixed Dose Combination Formulation, Rin 150 And Individual Reference Drugs In Healthy Volunteers
- First Posted Date
- 2013-12-18
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT02014272
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 247
- Registration Number
- NCT02007512
- Locations
- 🇺🇸
Indiana University Health Hospital, Indianapolis, Indiana, United States
🇺🇸Indiana University Health Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Investigational Drug Services, Indianapolis, Indiana, United States
A Study To Taste Three New Types Of Crizotinib Formulation In Comparison Of An Oral Solution And To Measure The Amount Of Crizotinib In The Body After These Formulations Are Orally Given, Relative To Capsule Formulation
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2014-04-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 21
- Registration Number
- NCT02006277
- Locations
- 🇧🇪
Pfizer Investigational Site, Brussels, Belgium
Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease
- First Posted Date
- 2013-12-10
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 19
- Registration Number
- NCT02006290
- Locations
- 🇺🇸
Pfizer Investigational Site, Raleigh, North Carolina, United States
A Study To Examine The Distribution Of PF-05212377 In The Brain Of Healthy Volunteer Subjects Using Positron Emission Tomography And A Radioactive Tracer Following Oral Administration Of One Dose Of PF-05212377
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2014-04-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT02005991
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer
- Conditions
- Prostate CancerNonmetastatic Castration-Resistant Prostate CancerCancer of the Prostate
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1402
- Registration Number
- NCT02003924
- Locations
- 🇺🇸
Urological Associates of Southern Arizona, PC, Tucson, Arizona, United States
🇺🇸Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸UCLA Clark Urology Center, Los Angeles, California, United States
Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: Placebo ointment (Vehicle)
- First Posted Date
- 2013-12-04
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 69
- Registration Number
- NCT02001181
- Locations
- 🇨🇦
K. Papp Clinical Research, Waterloo, Ontario, Canada
🇨🇦SKiN Centre for Dermatology, Peterborough, Ontario, Canada
🇨🇦Innovaderm Research Inc., Montreal, Quebec, Canada
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2020-09-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 50
- Registration Number
- NCT01999972
- Locations
- 🇺🇸
Investigational Drug Services IUHSCC, Indianapolis, Indiana, United States
🇺🇸IU Health University Hospital, Indianapolis, Indiana, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Phase 1 Study to Characterize the Safety and Pharmacokinetics of Single Intravenous Dose of Lorazepam in Healthy Japanese Adult Subjects
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2014-03-03
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT01994668
- Locations
- 🇯🇵
Pfizer Investigational Site, Hachioji-shi, Tokyo, Japan